Fecal microbiota transplantation for ulcerative colitis

Altered abundance and composition of the gut microbiota, i.e., dysbiosis, is reported to be involved in the pathogenesis of various diseases including not only gastrointestinal diseases but also metabolic, neurological, and autoimmune disorders. Fecal microbiota transplantation (FMT) aims to correct...

Full description

Bibliographic Details
Main Author: Katsuyoshi Matsuoka
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Immunological Medicine
Subjects:
Online Access:http://dx.doi.org/10.1080/25785826.2020.1792040
id doaj-d00674d46fe244f4979b43380d55251f
record_format Article
spelling doaj-d00674d46fe244f4979b43380d55251f2021-03-18T16:25:27ZengTaylor & Francis GroupImmunological Medicine2578-58262021-01-01441303410.1080/25785826.2020.17920401792040Fecal microbiota transplantation for ulcerative colitisKatsuyoshi Matsuoka0Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical CenterAltered abundance and composition of the gut microbiota, i.e., dysbiosis, is reported to be involved in the pathogenesis of various diseases including not only gastrointestinal diseases but also metabolic, neurological, and autoimmune disorders. Fecal microbiota transplantation (FMT) aims to correct dysbiosis by administrating feces collected from donors and thus treat the underlying disease. Ulcerative colitis (UC) is a disease characterized by chronic inflammation in the large intestine. Patients with UC have been reported to have dysbiosis, and more specifically, reduced diversity and abundance of the gut microbiota. FMT has been tried as a treatment for UC. Favorable effects of FMT on UC had been reported in case reports or case series. Recently, four randomized controlled trials of FMT for UC were published. Three of the four studies reported that FMT was more effective than control treatment. Thus, FMT is considered as a promising treatment for UC; however, there are many issues to solve before FMT can become a standard therapy for UC including donor selection, administration routes, frequencies, easy-to-administer formulation development, and optimal patient population.http://dx.doi.org/10.1080/25785826.2020.1792040ulcerative colitisdysbiosisfecal microbiota transplantationgut microbiota
collection DOAJ
language English
format Article
sources DOAJ
author Katsuyoshi Matsuoka
spellingShingle Katsuyoshi Matsuoka
Fecal microbiota transplantation for ulcerative colitis
Immunological Medicine
ulcerative colitis
dysbiosis
fecal microbiota transplantation
gut microbiota
author_facet Katsuyoshi Matsuoka
author_sort Katsuyoshi Matsuoka
title Fecal microbiota transplantation for ulcerative colitis
title_short Fecal microbiota transplantation for ulcerative colitis
title_full Fecal microbiota transplantation for ulcerative colitis
title_fullStr Fecal microbiota transplantation for ulcerative colitis
title_full_unstemmed Fecal microbiota transplantation for ulcerative colitis
title_sort fecal microbiota transplantation for ulcerative colitis
publisher Taylor & Francis Group
series Immunological Medicine
issn 2578-5826
publishDate 2021-01-01
description Altered abundance and composition of the gut microbiota, i.e., dysbiosis, is reported to be involved in the pathogenesis of various diseases including not only gastrointestinal diseases but also metabolic, neurological, and autoimmune disorders. Fecal microbiota transplantation (FMT) aims to correct dysbiosis by administrating feces collected from donors and thus treat the underlying disease. Ulcerative colitis (UC) is a disease characterized by chronic inflammation in the large intestine. Patients with UC have been reported to have dysbiosis, and more specifically, reduced diversity and abundance of the gut microbiota. FMT has been tried as a treatment for UC. Favorable effects of FMT on UC had been reported in case reports or case series. Recently, four randomized controlled trials of FMT for UC were published. Three of the four studies reported that FMT was more effective than control treatment. Thus, FMT is considered as a promising treatment for UC; however, there are many issues to solve before FMT can become a standard therapy for UC including donor selection, administration routes, frequencies, easy-to-administer formulation development, and optimal patient population.
topic ulcerative colitis
dysbiosis
fecal microbiota transplantation
gut microbiota
url http://dx.doi.org/10.1080/25785826.2020.1792040
work_keys_str_mv AT katsuyoshimatsuoka fecalmicrobiotatransplantationforulcerativecolitis
_version_ 1724215401747841024